Squarepoint
FNCH

Squarepoint’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Squarepoint’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$485K – 3871
2021
Q1 		$485K Buy
+1,000
New +$509K ﹤0.01% 2053

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Squarepoint's FNCH Position: Q2 2021 in Review

Squarepoint sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2021, closing a stake of 1,000 shares — an estimated $485K sold.

Squarepoint first reported a position in FNCH in Q1 2021 and held it in 1 quarter. The position peaked at $485K in Q1 2021. 45 funds tracked by Wall St. Rank hold FNCH as of Q2 2021.

  • Squarepoint reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 1,000 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2021, an estimated $485K.
  • Squarepoint first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Squarepoint's Finch Therapeutics Group, Inc. Common Stock position peaked at $485K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.